FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer

NCT00020202 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

NIH

Sponsor class

Conditions

Extensive Stage Small Cell Lung Cancer
Stage IIIA Non-small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer
Recurrent Small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer

Interventions

DRUG: FR901228

Sponsor

National Cancer Institute (NCI)